Patents by Inventor Tusharmouli Mukherjee

Tusharmouli Mukherjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220202698
    Abstract: Provided herein are the extended release pharmaceutical composition suitable for once or twice daily dosing comprising riociguat and at least one or more pharmaceutically acceptable excipients. The present invention also relates to method for preparing extended release composition and method of using these dosage forms for the treatment of pulmonary hypertension and related diseases. The present invention provides extended release composition of riociguat which are expected to exhibit desired technical attributes such as assay, stability and release profile suitable for once or twice daily administration.
    Type: Application
    Filed: December 27, 2021
    Publication date: June 30, 2022
    Applicant: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Rakesh Kumar Singh
  • Patent number: 11318145
    Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: May 3, 2022
    Inventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Rakesh K. Singh, Saurabh Srivastava
  • Patent number: 11311518
    Abstract: Disclosed are the injection compositions of ?3 adrenoreceptor agonists such as mirabegron or their pharmaceutically acceptable salts or solvates or esters thereof. The present invention also relates to methods for preparing injection compositions and methods of using these dosage forms for the treatment of obesity, other related metabolic diseases, and reduction/removal of fat. The injection compositions as per the present invention have advantages of simple preparation, simple and convenient application, easy absorption, and better effect of treating. The compositions can also be used in cases where oral administration of the drug is not possible due to underlying conditions or concerns around inadequate oral absorption. The injection compositions as per the present invention have desirable pharmaceutical technical attributes.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: April 26, 2022
    Assignee: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Tusharmouli Mukherjee, Nagabasayya R Chikkamath
  • Publication number: 20220000843
    Abstract: Provided herein are the long-acting injection compositions of ?3 adrenoreceptor agonists like mirabegron or their pharmaceutically acceptable salts or esters thereof. The present invention also relates to methods for preparing long-acting injection compositions and methods of using these dosage forms for the treatment of obesity, metabolic diseases, and other diseases as described herein. The long-acting injection compositions as per the present invention have desirable pharmaceutical technical attributes.
    Type: Application
    Filed: June 30, 2021
    Publication date: January 6, 2022
    Applicant: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Tusharmouli Mukherjee
  • Publication number: 20210369619
    Abstract: The present invention relates to the transmucosal dosage forms like sublingual pharmaceutical compositions comprising antiviral molecules like favipiravir, remdesivir, baloxavir marboxil, molnupiravir, besifovir, raltegravir, GS-441524, ravidasvir, and other antiviral drugs. The present invention also relates to methods for preparing these transmucosal pharmaceutical compositions. Compositions prepared as per the present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions prepared as per the present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration, and dissolution. The compositions prepared as per the present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19).
    Type: Application
    Filed: May 25, 2021
    Publication date: December 2, 2021
    Applicant: Jubilant Generics Limited
    Inventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Anil Jain, Pankaj Soni, Gaurav Navinbhai Mistry, Nilesh Jaiswal
  • Publication number: 20210353546
    Abstract: The present invention relates to a pharmaceutical composition comprising a combination of mirabegron and solifenacin or their pharmaceutically acceptable salts, wherein the composition comprises mini-tablets, multiparticulates, inlay tablets, or bilayer tablets. The prior art discloses restrictive formulation techniques and suggests complexity for preparing the combination in a single formulation to achieve the desired technical attributes. The test formulations are stable and exhibit desired pharmaceutical technical attributes. The invention also relates to the use of the pharmaceutical composition of the present invention in the treatment of various diseases like overactive bladder and other related therapeutic indications.
    Type: Application
    Filed: May 11, 2021
    Publication date: November 18, 2021
    Applicant: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Tusharmouli Mukherjee
  • Publication number: 20210275539
    Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Applicant: Jubilant Generics Limited
    Inventors: Indranil Nandi, TUSHARMOULI MUKHERJEE, Dinesh Kumar, Rakesh K. Singh, Saurabh Srivastava
  • Patent number: 9114171
    Abstract: A liquid composition comprising racecadotril and cyclodextrin.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: August 25, 2015
    Assignee: McNeil-PPC, Inc.
    Inventors: Der-Yang Lee, Tusharmouli Mukherjee
  • Patent number: 9084721
    Abstract: A liquid composition comprising racecadotril and cyclodextrin.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: July 21, 2015
    Assignee: McNeil-PPC, Inc.
    Inventors: Der-Yang Lee, Tusharmouli Mukherjee
  • Publication number: 20140274948
    Abstract: A liquid composition comprising racecadotril and cyclodextrin.
    Type: Application
    Filed: December 23, 2013
    Publication date: September 18, 2014
    Applicant: McNeil-PPC, Inc.
    Inventors: Der-Yang Lee, Tusharmouli Mukherjee
  • Publication number: 20140005261
    Abstract: A liquid composition comprising racecadotril and cyclodextrin.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 2, 2014
    Applicant: McNeil-PPC, Inc.
    Inventors: Der-Yang Lee, Tusharmouli Mukherjee